ArticleCurrent medicinal chemistry2025
A Scoping Review of Rho Kinase Inhibitors and their Role in Glaucoma Treatment.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Rho Kinase Inhibitor RKI-1447 on Dexamethasone-Induced Ocular Hypertension and Its Molecular Mechanisms in Sprague-Dawley Rats.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this scoping review is to provide researchers with a comprehensive knowledge map and identify existing knowledge gaps.
introductionGlaucoma is the leading cause of irreversible blindness worldwide. ROCK inhibitors are a novel class of intraocular pressure-lowering drugs that specifically target trabecular meshwork cells. Current research on ROCK inhibitors is dispersed across multiple directions, and their precise mechanisms of action in glaucoma treatment remain incompletely understood. For these reasons, we sought to integrate the existing evidence using a scoping review approach.
methodsRelevant articles published between 2014 and 2024 were identified and screened using keywords in the PubMed and Embase databases. Articles were analyzed based on the inclusion and exclusion criteria.
resultsThe collected studies were categorized into three main themes: intraocular pressure reduction, neuroprotection, and anti-fibrosis. A total of 23 articles were included in the review. We found that studies related to intraocular pressure reduction accounted for the majority (approximately 74%), while research on neuroprotection and anti-fibrosis was relatively limited (approximately 14% each). Furthermore, among the 23 included articles, only one was a systematic review or meta-analysis.
conclusionROCK inhibitors directly act on the trabecular meshwork to lower IOP and have potential neuroprotective and anti-fibrotic effects. However, these potential effects require further clinical trials to validate their efficacy in humans. In the future, more systematic reviews and meta-analyses are also needed to integrate and summarize the current primary research findings.
Indexed as
Identifiers
39931985What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.